NEW YORK, NY / ACCESSWIRE / December 20, 2022 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.
FRSH Shareholders Click Here: https://www.zlk.com/pslra-1/freshworks-class-action-loss-submission-form?prid=34813&wire=1
SEDG Shareholders Click Here: https://www.zlk.com/pslra-1/solaredge-class-action-submission-form?prid=34813&wire=1
EIGR Shareholders Click Here: https://www.zlk.com/pslra-1/eiger-biopharmaceuticals-class-action-lawsuit-submission-form?prid=34813&wire=1
* ADDITIONAL INFORMATION BELOW *
Freshworks Inc. (NASDAQ:FRSH)
This lawsuit is on behalf of persons and entities that purchased Freshworks common stock pursuant to and/or traceable to documents issued in connection with the Company’s initial public offering.
Lead Plaintiff Deadline : January 3, 2023
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/freshworks-class-action-loss-submission-form?prid=34813&wire=1
According to the complaint, the documents used to effectuate Freshworks’ initial public offering were false and misleading and omitted to state that, at the time of the initial public offering, the Company’s business had encountered obstacles. As a result of these obstacles, Freshworks’ net dollar retention rate was plateauing, and its revenue growth rate and billings were decelerating.
SolarEdge Technologies, Inc. (NASDAQ:SEDG)
This lawsuit is on behalf of a class consisting of persons who purchased or otherwise acquired common shares of SolarEdge stock between August 6, 2022 to October 19, 2022, both dates inclusive.
Lead Plaintiff Deadline : January 3, 2023
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/solaredge-class-action-submission-form?prid=34813&wire=1
According to the filed complaint, (i) the designs of the power optimizers, inverters, and components thereof used to develop SolarEdge’s products potentially originated with and were misappropriated from Ampt LLC (“Ampt”), a competitor in the renewable energy industry; (ii) Ampt made claims against the Company for misappropriating Ampt’s patented technology, (iii) evidentiary support existed for the allegations that SolarEdge misappropriated certain patents relating to the design and development of the Company’s power optimizers and inverters; (iv) as a result, SolarEdge faced a threat of regulatory and/or court action, which could prohibit the import, marketing, and sale of its power optimizers and inverters, including solar energy systems that contain such products; which in turn (v) seriously threatened SolarEdge’s ability to monetize on their solar energy systems that contain the power optimizers and inverters in the United States and generate revenue; and (vi) certain revenues generated from the sale of power optimizers and inverters were potentially based on SolarEdge’s unlawful activities, including the misappropriation of patented designs by Ampt.
Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR)
EIGR Lawsuit on behalf of: investors who purchased March 10, 2021 – October 4, 2022
Lead Plaintiff Deadline : January 9, 2023
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/eiger-biopharmaceuticals-class-action-lawsuit-submission-form?prid=34813&wire=1
According to the filed complaint, during the class period, Eiger BioPharmaceuticals, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) defendants overstated Eiger’s clinical and regulatory drug development expertise; (ii) defendants failed to properly assess, and/or ignored issues with, the design of the TOGETHER study and its ability to support the Emergency Use Authorization (“EUA”) for the Company’s product candidate, peginterferon lambda ; (iii) there were issues with the conduct of the TOGETHER study and/or the TOGETHER study was not properly designed for the peginterferon lambda EUA in the current context of the pandemic; (iv) as a result, the U.S. Food and Drug Administration was unlikely to approve the submission of a peginterferon lambda EUA; (v) as a result of all the foregoing, peginterferon lambda’s regulatory and commercial prospects for the treatment of COVID-19 were overstated; and (vi) as a result, the Company’s public statements were materially false and misleading at all relevant times.
You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Eduard Korsinsky, Esq.
55 Broadway, 10th Floor
New York, NY 10006
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com
SOURCE:Levi & Korsinsky, LLP
View source version on accesswire.com:
https://www.accesswire.com/732558/CLASS-ACTION-UPDATE-for-FRSH-SEDG-and-EIGR-Levi-Korsinsky-LLP-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders